Solifenacin (Succinate)
CAT:
804-HY-A0002-02
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Solifenacin (Succinate)
- CAS Number: 242478-38-2
- UNSPSC Description: Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
- Target Antigen: mAChR
- Type: Reference compound
- Related Pathways: GPCR/G Protein;Neuronal Signaling
- Applications: Neuroscience-Neuromodulation
- Field of Research: Neurological Disease; Cancer
- Assay Protocol: https://www.medchemexpress.com/Solifenacin-Succinate.html
- Purity: 99.95
- Solubility: DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)
- Smiles: O=C(O[C@H]1CN2CCC1CC2)N3[C@H](C4=C(CC3)C=CC=C4)C5=CC=CC=C5.O=C(CCC(O)=O)O
- Molecular Weight: 480.55
- References & Citations: [1]Krishna SR, Rao BM, Rao NS.A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.J Chromatogr Sci. 2010 Nov;48(10):807-10.|[2]Ohtake A, Sato S, Sasamata M, Miyata K.The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4.|[3]Hoffstetter S, Leong FC.Solifenacin succinate for the treatment of overactive bladder.Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50.|[4]Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Int J Clin Pract. 2008 Nov;62(11):1675-83.|[5]Imamura T, et al.Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033.Neurourol Urodyn. 2017 Apr;36(4):1026-1033. |Int J Nanomedicine. 2024 Aug 15:19:8353-8371.|J Chem Neuroanat. 2023 Dec 18:102375.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched